Allergan presents data on treatments for AMD and glaucoma
The company highlighted a potential “first-in-class” treatment for reducing intraocular pressure
Allergan presented two-year data from clinical studies of Abicipar in patients with neovascular AMD, as well as presenting data on Bimatoprost Sustained Release.
It highlighted that Bimatoprost Sustained Release has the potential to be a “first-in-class” biodegradable implant for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Senior vice president and head of global clinical development at Allergan, Dr Yehia Hashad, said: “The data presented at AAO for our late stage, investigational assets, Abicipar and Bimatoprost Sustained-Release, showcase our continued commitment to innovation in ophthalmology. We’re excited to share data that may redefine treatment approaches in neovascular age-related macular degeneration and glaucoma, and may improve upon the current state of patient care.”
Image credit: Pixabay/Tobias Dahlberg